WELLCOVORIN
LOE ApproachingNDAORALTABLET
Approved
Jul 1983
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
WELLCOVORIN is an oral small-molecule tablet approved in 1983 by GSK. The mechanism of action and specific indications are not publicly detailed in available data, limiting assessment of its therapeutic role. It represents a mature, legacy product in the small-molecule space.
LOE Approaching
Approaching loss of exclusivity with moderate competitive pressure (30/100) suggests a contracting team focused on cost management and generic transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job postings indicate minimal active hiring for WELLCOVORIN roles, reflecting its LOE-approaching lifecycle stage. Working on this product offers stability but limited career acceleration; value lies in lifecycle management expertise and preparation for post-LOE commercial transitions.
Brand ManagerMarket Access Manager
Worked on WELLCOVORIN at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.